Carboxylated gold nanoparticles inhibit bone erosion by disturbing the acidification of an osteoclast absorption microenvironment

被引:21
作者
Bai, Xue [1 ]
Gao, Yuan [1 ]
Zhang, Mingyi [1 ]
Chang, Ya-nan [1 ]
Chen, Kui [1 ]
Li, Juan [1 ]
Zhang, Jiaxin [1 ]
Liang, Yuelan [1 ]
Kong, Jianglong [1 ]
Wang, Yujiao [1 ]
Liang, Wei [2 ]
Xing, Gengyan [2 ]
Li, Wei [3 ]
Xing, Gengmei [1 ]
机构
[1] Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, 19B YuquanLu, Beijing, Peoples R China
[2] Gen Hosp Chinese Peoples Armed Police Forces, Dept Orthoped, Beijing, Peoples R China
[3] Harbin Inst Technol, Harbin Hosp 1, Beijing, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
DIFFERENTIATION; OSTEOPOROSIS; MECHANISMS; SUBSET; ATPASE; TUMORS;
D O I
10.1039/c9nr09698a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Hyperactive osteoclasts (OCs) are a fundamental reason for excessive bone resorption and consequent osteoporosis that lead to one-third of the patients sustaining a fracture. OCs, with the help of acidifying vesicles containing vacuolar-type H+-ATPase (V-ATPase), transport cytoplasmic protons into a resorptive pit and create an acidic microenvironment where proteolytic enzymes degrade the bone matrix. Here, we report a previously undescribed application of gold nanoparticles (AuNPs) to inhibit excessive bone resorption by regulating the acidic microenvironment in which OCs resorb bone. Internalized AuNPs, with relatively abundant carboxyl groups, eventually accumulate in the membrane of the intracellular vesicles and interact with the V0 domain of V-ATPase, which prevents it from recruiting the V1 domain. This destroys the acid-secretion function of OCs. The therapeutic effect of AuNPs on bone resorption was assessed in an established lipopolysaccharide-induced bone erosion mouse model. Micro-computed tomography, histology, and tartrate-resistant acid phosphatase staining showed that AuNPs significantly reduced bone erosion. In summary, AuNPs are promising nano-functional materials for repairing bone defects by regulating OC acid secretion.
引用
收藏
页码:3871 / 3878
页数:8
相关论文
共 44 条
  • [1] Inflammation, cancer, and bone loss
    Abu-Amer, Yousef
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) : 427 - 433
  • [2] Nanoparticles with High-Surface Negative-Charge Density Disturb the Metabolism of Low-Density Lipoprotein in Cells
    Bai, Xue
    Zhang, Jiaxin
    Chang, Ya-Nan
    Gu, Weihong
    Lei, Runhong
    Qin, Yanxia
    Xia, Shibo
    Ma, Sihan
    Liang, Yuelan
    Chen, Kui
    Li, Juan
    Sun, Baoyun
    Xing, Gengmei
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (09)
  • [3] Fluorescence Lifetime Measurements and Biological Imaging
    Berezin, Mikhail Y.
    Achilefu, Samuel
    [J]. CHEMICAL REVIEWS, 2010, 110 (05) : 2641 - 2684
  • [4] Osteopetrosis Mutation R444L Causes Endoplasmic Reticulum Retention and Misprocessing of Vacuolar H+-ATPase a3 Subunit
    Bhargava, Ajay
    Voronov, Irina
    Wang, Yongqiang
    Glogauer, Michael
    Kartner, Norbert
    Manolson, Morris F.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (32) : 26829 - 26839
  • [5] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Black, Dennis M.
    Delmas, Pierre D.
    Eastell, Richard
    Reid, Ian R.
    Boonen, Steven
    Cauley, Jane A.
    Cosman, Felicia
    Lakatos, Peter
    Leung, Ping Chung
    Man, Zulema
    Mautalen, Carlos
    Mesenbrink, Peter
    Hu, Huilin
    Caminis, John
    Tong, Karen
    Rosario-Jansen, Theresa
    Krasnow, Joel
    Hue, Trisha F.
    Sellmeyer, Deborah
    Eriksen, Erik Fink
    Cummings, Steven R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) : 1809 - 1822
  • [6] Postmenopausal Osteoporosis
    Black, Dennis M.
    Rosen, Clifford J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03) : 254 - 262
  • [7] Osteoclast differentiation and activation
    Boyle, WJ
    Simonet, WS
    Lacey, DL
    [J]. NATURE, 2003, 423 (6937) : 337 - 342
  • [8] Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
    Delmas, PD
    Ensrud, KE
    Adachi, JD
    Harper, KD
    Sarkar, S
    Gennari, C
    Reginster, JY
    Pols, HAP
    Recker, RR
    Harris, ST
    Wu, WT
    Genant, HK
    Black, DM
    Eastell, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) : 3609 - 3617
  • [9] V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis
    Duan, Xiaohong
    Yang, Shaoqing
    Zhang, Lei
    Yang, Tielin
    [J]. THERANOSTICS, 2018, 8 (19): : 5379 - 5399
  • [10] Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]